Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)
Data published in Antimicrobial Agents and Chemotherapy demonstrate CD101 has superior tissue and lesion penetration compared to the current standard of care
While the
The study is the first to use MALDI-MS imaging, a powerful tool that
enables investigators to acquire molecular information about drug
distributions in tissues, as well as drug quantification methods, in a
clinically relevant mouse intra-abdominal abscesses model. It compared
single-dose treatments of CD101 to multiple-dose treatments of
micafungin at doses that approximated human plasma exposures for each
drug at their expected or
“The results from this cutting-edge study showcase the potential
advantages of CD101 as compared to currently marketed antifungals to
effectively treat an infection for which patients and medical
professionals desperately need new treatment options,” said
“The approximately 40 percent failure rate experienced by patients with
invasive candidiasis may be related to findings that current
echinocandin therapies cannot deliver sufficient concentrations to
infection sites,” said
About Fungal Infections
Approximately 97,000 Americans die from hospital-related fungal
infections each year and 90 percent of these infections are caused by
two common fungi, Candida and Aspergillus. The emergence
of a new and virulent fungal infection called Candida auris (C.
auris) is also a growing public health concern due its resistance to
existing antifungal agents. As of
About
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101 IV, through Phase 2
and developing CD201, its bispecific antibiotic immunotherapy, for the
treatment of multi-drug resistant Gram-negative bacterial infections.
CD101 IV has improved pharmacokinetics compared to existing
echinocandins and has the potential for expanded utility across patient
settings. CD101 IV is the only once-weekly product candidate in
development for the treatment and prevention of life-threatening
invasive fungal infections. CD201 is the first drug candidate selected
from Cidara’s novel Cloudbreak™ platform, the first immunotherapy
discovery platform designed specifically to create compounds that direct
a patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara recently received a grant for up to
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, and other attributes
of CD101, including the potential for this compound to successfully
treat and prevent fungal infections compared to current antifungal
agents. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of Cidara’s
preclinical studies and clinical trials; regulatory developments in
View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005618/en/
Source:
INVESTORS:
Westwicke Partners, LLC
Robert H. Uhl,
858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA:
Sam
Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com